CORONA Remedies Limited, an India-focused pharmaceutical company with a strong presence in Women’s Healthcare, Cardio-Diabeto, Pain Management and Urology therapies, has received European Union Good Manufacturing Practice (EU-GMP) Compliance Certification.

The certification is for its hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla, Ahmedabad.

The company said the approvals mark a significant milestone in strengthening its global manufacturing and quality credentials, reinforcing its commitment to international quality standards, scientific excellence and advanced manufacturing capabilities. 

According to the company, the certifications were achieved in a short timeframe, reflecting its quality-driven culture, robust compliance systems and operational excellence.

The development is expected to enhance CORONA’s position as a trusted global partner in hormone therapies and other therapeutic segments.

The Bhayla facility in Ahmedabad serves as one of the company’s key manufacturing hubs and has been central to its efforts to align production processes with global regulatory requirements. 

Viral Sitwala, Executive Director, CORONA Remedies Limited, said, “We view this accreditation as a reflection of our unwavering commitment to quality and our philosophy of ‘One World. One Quality.’ By adopting uniform global practices, we aim to serve both the Indian market and other regulated/semi-regulated markets from this facility.”